Solide Tumoren - Atemwege und Lunge - Nichtkleinzelliges Bronchialkarzinom (NSCLC) - Weiterführende Informationen

Leitlinien

siehe SCLC

Literatur

1. National Lung Screening Trail Research Team: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409
2. Detterbeck FC et al: The new lung cancer staging system. Chest 2009; 136: 260–71
3. Travis WD et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary classification of lung adenocarcinoma. J Thoracic Oncol 2011; 6: 244-85
4. Kris MG et al: Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI`s Lung Cancer Mutation Consortium (LCMC).J Clin Oncol 2011; 29: abstr 7506
5. Pignon JP et al: Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group, J Clin Oncol 2007; 25:1377–82
6. Kreuter et al: Randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb): TREAT. J Clin Oncol 2011; 29: abstr 7002
7. Albain KS et al: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379–86
8. Kwak EL et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-703
9. Sandler A et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006; 355: 2542–50
10. Pirker R et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525–31
11. Mok TS et al: Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med 2009; 361:947–57
12. Rosell R et al: Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patient (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 2011; 29: abstr 7503
13. Di Maio M et al: Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 1836–43
14. Di Maio M et al: Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-call lung cancer. J Clin Oncol 2007,25:1377-82
15. Shepherd FA et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–32
16. Kim ES et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809–18
17. Cappuzzo F et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, random-ised, placebo-controlled phase 3 study. Lancet Oncol (2010) 11: 521–9
18. Paz-Ares LG et al: PARAMOUNT: Phase III study of maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with Pem plus cisplatin for advanced nonsquamous non-small cell lung cancer. J Clin Oncol 2011; 29: abstr #7510